Data Committee Recommends Veru's COVID-19 Trial To Continue Unmodified

 The Independent Data Monitoring Committee (IDMC) has conducted a planned conditional power analysis of the first 75 randomized patients in Veru Inc's 

VERU +0.31%

 (Get Free Alerts for VERU) Phase 3 trial of sabizabulin.

• The trial included hospitalized patients with moderate to severe COVID-19 infection at high risk for acute respiratory distress syndrome (ARDS) and death.
• IDMC has concluded that the clinical study should continue as initially designed.
•  The IDMC performed this planned conditional statistical power analysis and review of the safety of the first 75 study patients to reach the primary endpoint. 
• Current full study recruitment is on track to yield clinical results in 1H of 2022.
• The Phase 3 COVID-19 clinical study is evaluating daily oral 9 mg sabizabulin for up to 21 days versus placebo in 300 hospitalized patients.
• The primary efficacy endpoint will be the proportion of patients that die on study up to Day 60. 

https://www.benzinga.com/general/biotech/22/02/25601573/data-committee-recommends-verus-covid-19-trial-to-continue-unmodified